Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy
| Autor: | Ozdemir, Yurday, Topkan, Erkan, Mertsoylu, Huseyin, Selek, Ugur |
|---|---|
| Přispěvatelé: | Selek, Uğur (ORCID 0000-0001-8087-3140 & YÖK ID 27211), Özdemir, Yurday, Topkan, Erkan, Mertsoylu, Hüseyin, School of Medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.medical_treatment Medicine Oncology survival results Gastroenterology chemoradiotherapy 03 medical and health sciences 0302 clinical medicine Prognostic nutritional index Non-small-cell lung carcinoma Prognosis Chemoradiotherapy Survival results Internal medicine non-small -cell lung carcinoma Carcinoma medicine Original Research Univariate analysis Chemotherapy Receiver operating characteristic business.industry Area under the curve prognostic nutritional index medicine.disease Confidence interval Radiation therapy 030104 developmental biology Cancer Management and Research 030220 oncology & carcinogenesis prognosis business |
| Zdroj: | Cancer Management and Research |
| ISSN: | 1179-1322 |
| Popis: | Purpose: to investigate the prognostic utility of the prognostic nutritional index (PNI) in stage IIIB non-small-cell lung carcinoma (NSCLC) patients undergoing concurrent chemoradiotherapy (CRT). Methods: a total of 358 stage IIIB NSCLC patients who received a total dose of 60-66 Gy (2 Gy/fraction) radiotherapy and >= 1 cycle(s) of platinum-based chemotherapy were analyzed. The receiver operating curve analysis was utilized to identify the optimal PNI cut-off value demonstrating a significant connection with the overall survival (OS), locoregional progression-free survival (LRPFS), and progression-free survival (PFS). Results: at a median follow-up time of 22.5 months (range: 2.4-123.5), 30.2% and 14% of the patients were still alive and free of disease progression, respectively.The median OS, LRPFS, and PFS were 25.2 [95% confidence interval (CI): 36.3-46.6 months], 15.4 (95% CI: 26.6-35.3 months), and 10.7 (95% CI: 36.8-69.9 months), individually, for the whole study accomplice. The ROC analysis revealed an optimum rounded cut-off that associated meaningfully with each of the OS [area under the curve (AUC): 84.1%; sensitivity: 75.9%;72.4% specificity], LRPFS (AUC: 92.4%; sensitivity: 87.9%; 85.1% specificity), and PFS (AUC: 80.1%; sensitivity: 73.7%; 71.6% specificity) at a value of 40.5. Comparative analyses revealed that the patients presenting with PNI 40.5. In univariate analyses, lower T-stage (1-2 vs 3-4; P< 0.001), lower N-stage (N2 vs N3; P< 0.001), anemia status (absent vs present; P< 0.001), weight loss status (= 5%; P< 0.001), and PM group (40.5; P NA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|